Related Experiment Video

Updated: Jul 19, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

39.9K

Device-Based Therapy for Resistant Hypertension: An Up-to-Date Review

Oussama Jami1,2, Youssef Tijani3, Aziz Et-Tahir4

  • 1High School of Technology in Salé, Materials, Energy and Acoustics Team Rabat, Mohammed V University in Rabat, Rabat, Morocco. oussamajami@research.emi.ac.ma.

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
|September 30, 2022
PubMed

Insights

Resistant hypertension (RH) is often uncontrolled due to medication non-adherence and high sympathetic activity. Device-based therapies offer a promising non-pharmacological treatment option for RH patients, supported by clinical trials.

Area of Science:

  • Cardiovascular Medicine
  • Hypertension Research
  • Medical Device Technology

Background:

  • Hypertension is a primary risk factor for cardiovascular disease, morbidity, and mortality.
  • Uncontrolled hypertension significantly worsens overall health outcomes.
  • Persistent uncontrolled hypertension, or resistant hypertension (RH), is characterized by medication non-adherence and increased sympathetic activity.

Purpose of the Study:

  • To review emerging non-pharmacological treatments for resistant hypertension (RH).
  • To discuss device-based therapies for RH and supporting clinical trial evidence.
  • To highlight the role of novel technologies in managing RH.

Main Methods:

  • Literature review of recent non-pharmacological treatments for RH.
  • Analysis of device-based RH therapy technologies and their clinical validation.
  • Discussion of clinical trials supporting device-based approaches.

Main Results:

  • Device-based approaches targeting RH show promise as a therapeutic option.
  • Several studies and clinical trials support the efficacy of these novel therapies.
  • Drug non-adherence and high sympathetic activity are identified as key contributors to RH.

Conclusions:

  • Novel device-based therapies represent a promising avenue for managing resistant hypertension.
  • Further research is needed to optimize RH system design.
  • Increased availability of randomized controlled trials is crucial for future validation.

Keywords:
Clinical trialsDevice-based therapyNon-invasivenessResistant hypertensionSympathetic nerve activity

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

283

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...